| abstract |
The present invention relates to the technical field of cell culture. It involves activating transcription factor 6β (ATF6B), or knockdown (using RNA interference) or gene knockdown of a combination of ceramide synthase 2 (CERS2) and TBC1 domain family member 20 (TBC1D20), which are secreted by cells function in the pathway. This downregulation results in improved secretion of biopharmaceutically relevant products produced in mammalian cells. In particular, the present invention relates to mammalian cells having enhanced secretion of recombinant therapeutic proteins compared to control cells, methods of producing said mammalian cells, methods for producing recombinant secreted therapeutic proteins, and use of said mammalian cells for increased secretion of recombinant therapeutic proteins Use of yields of recombinant secreted therapeutic proteins. |